Dr. Rosenzweig-Lipson holds significant expertise in screening strategies, in vivo models, translation, and clinical development strategy with more than three decades of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry and in biotech. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer. Most recently, as head of R&D, Dr. Rosenzweig-Lipson led the clinical development of AgeneBio’s lead asset through Phase 2B trials as well as the company’s preclinical development programs. Dr. Rosenzweig-Lipson earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.